4.8 Article

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Immunology

Phenotypical and functional specialization of FOXP3+ regulatory T cells

Daniel J. Campbell et al.

NATURE REVIEWS IMMUNOLOGY (2011)

Review Immunology

Induction of T cell anergy: integration of environmental cues and infectious tolerance

Pascal Chappert et al.

CURRENT OPINION IN IMMUNOLOGY (2010)

Review Immunology

FOXP3+ regulatory T cells in the human immune system

Shimon Sakaguchi et al.

NATURE REVIEWS IMMUNOLOGY (2010)

Review Immunology

Immune Therapy for Cancer

Michael Dougan et al.

ANNUAL REVIEW OF IMMUNOLOGY (2009)

Article Immunology

Human memory CCR4+CD8+ T cell subset has the ability to produce multiple cytokines

Takaaki Kondo et al.

INTERNATIONAL IMMUNOLOGY (2009)

Review Oncology

CCR4 as a novel molecular target for immunotherapy of cancer

Takashi Ishida et al.

CANCER SCIENCE (2006)

Article Medicine, Research & Experimental

In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines

Hiroyoshi Nishikawa et al.

JOURNAL OF CLINICAL INVESTIGATION (2006)

Review Immunology

Regulatory T cells, tumour immunity and immunotherapy

WP Zou

NATURE REVIEWS IMMUNOLOGY (2006)

Article Multidisciplinary Sciences

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

E Sato et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Article Medicine, Research & Experimental

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

J Dannull et al.

JOURNAL OF CLINICAL INVESTIGATION (2005)

Article Immunology

Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells

H Nishikawa et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2005)

Review Immunology

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

MJ Scanlan et al.

IMMUNOLOGICAL REVIEWS (2002)